

INTRODUCTION

Historically, the diagnosis of congenital and developmental anomalies has predominantly relied upon conventional cytogenetic techniques, such as Chromosomal Microarray Analysis (CMA) and Karyotyping. While effective in identifying chromosomal abnormalities, these methods may fail to elucidate the complex genetic determinants responsible for observed phenotypic variations. Advanced molecular techniques, such as Genome Sequencing (GS) and Exome Sequencing (ES), are complementary to these conventional cytogenetic modalities, offering a comprehensive understanding of molecular aberrations. The integration of traditional cytogenetic methodologies and molecular approaches has been shown to significantly enhance the precision of genetic diagnostics.

METHODS

This is a retrospective evaluation of 17 patients with well-known chromosomal disorders. Demographic data, clinical history, and diagnostic findings for patients who had reportable findings in addition to the chromosomal disorders were investigated.

A combination of molecular and cytogenetic testing was performed for 9 patients either as standard of care, or if the diagnosis could not be established by a single test. In 8 additional cases, GS or ES served as the primary diagnostic tools due to the broad differential diagnoses.

RESULTS




Figure 1. Distribution of biological sex, age, and phenotypes of all patients in the current study. A. Distribution of biological sex, B. Distribution of age, C. Distribution of phenotypes.

Table 1. All additional molecular findings identified in patients




Figure 2. Distribution of Chromosomal findings in all patients

Gene	Transcript	cDNA	Protein	Inheritance pattern	ACMG classification
<i>TYMP</i>	NM_001953.5	c.1040T>C	p.L347P	AR	Likely Pathogenic
<i>NBEA</i>	NM_001385012.1	c.3911dup	p.D1304Efs*11	AD	Pathogenic
<i>SYNE1</i>	NM_182961.4	c.18653C>A	p.S6218*	AD	Pathogenic
<i>LZTR1</i>	NM_006767.4	c.372C>T	p.V124=	AD	Likely Pathogenic
<i>RPGRIP1L</i>	NM_015272.5	c.632T>A	p.L211*	AR	Likely Pathogenic
<i>RPGRIP1L</i>	NM_015272.5	c.1104-2A>G		AR	Likely Pathogenic
<i>HERC2</i>	NM_004667.6	c.958G>A	p.G320R	AR	Likely Pathogenic
<i>HERC2</i>	NM_004667.6	c.7745C>T	p.A2582V	AR	Likely Pathogenic
<i>ANKRD11</i>	NM_013275.6	c.5659C>T	p.Q1887*	AD	Pathogenic
<i>MECP2</i>	NM_004992.3	c.1155_1200del	p.L386Afs*8	XL	Pathogenic
<i>UFSP2</i>	NM_018359.5	c.344T>A	p.V115E	AR	Likely Pathogenic
<i>GATA1</i>	NM_002049.4	c.159_160delinsAGTG	p.T54Vfs*84	XL	Likely Pathogenic
<i>NPRL3</i>	NM_001077350.3	c.189-1G>A		AD	Pathogenic
<i>SCN5A</i>	NM_000335.5	c.5362_5365del	p.S1787Rfs*46	AD	Likely Pathogenic
<i>MYH7</i>	NM_000257.4	c.3157C>T	p.R1053W	AD	Likely Pathogenic
<i>USH2A</i>	NM_206933.4	c.11754G>A	p.W3918*	AR	Pathogenic
<i>WFS1</i>	NM_006005.3	c.1523A>G	p.Y508C	AR	Likely Pathogenic

CONCLUSIONS

In summary, our results underscore the potency of integrating GS/ES and cytogenetic testing in unraveling the underlying molecular determinants responsible for specific developmental disorders, shedding light on the complexity of genetic disease etiology and the consideration of the possibility of a 'double hit' rather than prematurely attributing observed phenotypic variations to a 'phenotypic expansion' of a given gene.